scholarly journals Network Pharmacology and Inflammatory Microenvironment Strategy Approach to Finding the Potential Target of Siraitia grosvenorii (Luo Han Guo) for Glioblastoma

2021 ◽  
Vol 12 ◽  
Author(s):  
Juan Li ◽  
De Bi ◽  
Xin Zhang ◽  
Yunpeng Cao ◽  
Kun Lv ◽  
...  
Keyword(s):  
Complementary Therapy ◽  
Intracranial Tumor ◽  
Network Pharmacology ◽  
Immune Microenvironment ◽  
Standard Methods ◽  
Inflammatory Microenvironment ◽  
Siraitia Grosvenorii ◽  
The Central Nervous System ◽  
Primary Intracranial Tumor ◽  
Methods Of Treatment

Background: Glioblastoma (GBM) is the most common and aggressive primary intracranial tumor of the central nervous system, and the prognosis of GBM remains a challenge using the standard methods of treatment—TMZ, radiation, and surgical resection. Traditional Chinese medicine (TCM) is a helpful complementary and alternative medicine. However, there are relatively few studies on TCM for GBM.Purpose: We aimed to find the connection between TCM and anti-GBM.Study design: Network pharmacology and inflammatory microenvironment strategy were used to predict Siraitia grosvenorii (Luo Han Guo) target for treating glioblastoma.Methods: We mainly used network pharmacology and bioinformatics.Results: CCL5 was significantly highly expressed in GBM with poor prognostics. Uni-cox and randomForest were used to determine that CCL5 was especially a biomarker in GBM. CCL5 was also the target for SG and TMZ. The active ingredient of Luo Han Guo — squalene and CCL5 —showed high binding efficiency. CCL5, a chemotactic ligand, was enriched and positively correlated in eosinophils. CCL5 was also the target of Luo Han Guo, and its effective active integrate compound –— squalene — might act on CCL5.Conclusion: SG might be a new complementary therapy of the same medicine and food, working on the target CCL5 and playing an anti-GBM effect. CCL5 might affect the immune microenvironment of GBM.

Retinoblastoma as a Possible Primary Intracranial Tumor

Neurosurgery ◽  
1981 ◽  
Vol 9 (6) ◽  
pp. 706-709 ◽  
Author(s):  
Elizabeth Bullitt ◽  
Barbara J. Crain
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Intracranial Tumor ◽  
Intracranial Tumors ◽  
Retinal Lesion ◽  
The Central Nervous System ◽  
Primary Intracranial Tumor ◽  
Genetic Form

Abstract A 10-month-old infant with a small. unilateral, peripheral retinal lesion also had a large. well-encapsulated. suprasellar retinoblastoma. The primary vs. the metastatic nature of the intracranial tumor is considered. It is postulated that primary intracranial tumors may arise within areas of the central nervous system embryologically related to the retina in patients with the genetic form of retinoblastoma.

Angiofibroma of the middle cranial fossa

1971 ◽  
Vol 35 (1) ◽  
pp. 90-94 ◽  
Author(s):  
G. Vasudeva Iyer ◽  
N. D. Vaishya ◽  
A. Bhaktaviziam ◽  
G. M. Taori ◽  
Jacob Abraham
Keyword(s):  
Young Woman ◽  
Middle Cranial Fossa ◽  
Intracranial Tumor ◽  
Rare Occurrence ◽  
Content Type ◽  
Cranial Fossa ◽  
Primary Intracranial Tumor ◽  
Fine Print

✓ The rare occurrence of angiofibroma as a primary intracranial tumor in the middle cranial fossa is reported in a young woman, and related reports are reviewed.

scholarly journals Yoga as an Alternative and Complementary Therapy for Patients Suffering From Anxiety

2012 ◽  
Vol 18 (1) ◽  
pp. 15-22 ◽  
Author(s):  
Manoj Sharma ◽  
Taj Haider
Keyword(s):  
United States ◽  
Systematic Review ◽  
Side Effects ◽  
English Language ◽  
Complementary Therapy ◽  
The United States ◽  
Alternative Methods ◽  
Restless Leg Syndrome ◽  
Alternative And Complementary Therapy ◽  
Methods Of Treatment

Anxiety disorders are one of the most common psychiatric disorders plaguing the United States. Comorbidities include depression, restless leg syndrome, cancer, and hypertension. The side effects and the high-costs associated with the current pharmacological therapies necessitate exploration of alternative methods of treatment. To determine the efficacy of yoga as a treatment option a systematic review is presented here. The criteria for inclusion in this review were as follows: ( a) published in the English language ( b) published between the period January 2010 and May 2012, ( c) include any form of yoga as a part of or an entire intervention, ( d) use any quantitative study design, and ( e) measure anxiety as an outcome. A total of 27 studies met these criteria. Of these, 19 demonstrated a significant reduction in state and/or trait anxiety. Limitations include a lack of theory-based approaches, subjects experiencing comorbidities, and the use of numerous instruments to measure anxiety outcomes.

scholarly journals A Review of Various Antioxidant Compounds and their Potential Utility as Complementary Therapy in Multiple Sclerosis

Nutrients ◽  
2019 ◽  
Vol 11 (7) ◽  
pp. 1528 ◽  
Author(s):  
Elzbieta Dorota Miller ◽  
Angela Dziedzic ◽  
Joanna Saluk-Bijak ◽  
Michal Bijak
Keyword(s):  
Oxidative Stress ◽  
Multiple Sclerosis ◽  
Complex Disease ◽  
Early Stage ◽  
Symptomatic Treatment ◽  
Complementary Therapy ◽  
Antioxidant Compounds ◽  
Inflammatory Processes ◽  
The Central Nervous System ◽  
Stress Mediators

Multiple sclerosis (MS) is a complex disease of the central nervous system (CNS). The etiology of this multifactorial disease has not been clearly defined. Conventional medical treatment of MS has progressed, but is still based on symptomatic treatment. One of the key factors in the pathogenesis of MS is oxidative stress, enhancing inflammation and neurodegeneration. In MS, both reactive oxygen and nitrogen species are formed in the CNS mainly by activated macrophages and microglia structures, which can lead to demyelination and axon disruption. The course of MS is associated with the secretion of many inflammatory and oxidative stress mediators, including cytokines (IL-1b, IL-6, IL-17, TNF-α, INF-γ) and chemokines (MIP-1a, MCP-1, IP10). The early stage of MS (RRMS) lasts about 10 years, and is dominated by inflammatory processes, whereas the chronic stage is associated with neurodegenerative axon and neuron loss. Since oxidative damage has been known to be involved in inflammatory and autoimmune-mediated processes, antioxidant therapy could contribute to the reduction or even prevention of the progression of MS. Further research is needed in order to establish new aims for novel treatment and provide possible benefits to MS patients. The present review examines the roles of oxidative stress and non-pharmacological anti-oxidative therapies in MS.

scholarly journals PATH-38. METASTATIC MENINGIOMA CAUSING CHRONIC RESPIRATORY FAILURE

2020 ◽  
Vol 22 (Supplement_2) ◽  
pp. ii172-ii172
Author(s):  
Dhiren Wallace ◽  
Gerald Wallace ◽  
Nichols Fenwick ◽  
John Vender ◽  
Ambika Sood ◽  
...  
Keyword(s):  
Respiratory Failure ◽  
Case Reports ◽  
Venous Drainage ◽  
Intracranial Tumor ◽  
Cns Tumors ◽  
Malignant Meningioma ◽  
Hypercapnic Respiratory Failure ◽  
Grade Ii ◽  
Primary Intracranial Tumor ◽  
Grade Iii

Abstract Meningiomas are the most common primary intracranial tumor accounting for almost 37% of all CNS tumors. Malignant meningiomas are uncommon, accounting for 0.5% of all meningiomas. Malignant meningioma that is metastatic outside the cranium/skull is even rarer, with only a few case reports. Metastases to the lung and abdomen have been reported and thought to travel via venous drainage. WHO Grading suggest that Grade III meningiomas have the greatest potential to metastasize extra-cranially. We present the case for the 47-year-old Senegalese American man with biopsy proven Grade II meningioma metastatic to his lungs with resultant hypercapnic respiratory failure.

scholarly journals The microenvironment of brain metastases from solid tumors

2021 ◽  
Vol 3 (Supplement_5) ◽  
pp. v121-v132
Author(s):  
Ethan S Srinivasan ◽  
Krutika Deshpande ◽  
Josh Neman ◽  
Frank Winkler ◽  
Mustafa Khasraw
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Brain Metastases ◽  
Intracranial Tumor ◽  
Malignant Cells ◽  
Complex Interplay ◽  
Dismal Prognosis ◽  
Medical Need ◽  
Metabolic Conditions ◽  
The Central Nervous System

Abstract Brain metastasis (BrM) is an area of unmet medical need that poses unique therapeutic challenges and heralds a dismal prognosis. The intracranial tumor microenvironment (TME) presents several challenges, including the therapy-resistant blood–brain barrier, a unique immune milieu, distinct intercellular interactions, and specific metabolic conditions, that are responsible for treatment failures and poor clinical outcomes. There is a complex interplay between malignant cells that metastasize to the central nervous system (CNS) and the native TME. Cancer cells take advantage of vascular, neuronal, immune, and anatomical vulnerabilities to proliferate with mechanisms specific to the CNS. In this review, we discuss unique aspects of the TME in the context of brain metastases and pathways through which the TME may hold the key to the discovery of new and effective therapies for patients with BrM.

scholarly journals Glioblastoma: a molecular genetic portrait and modern therapeutic strategies for drug treatment

2021 ◽  
Vol 8 (3) ◽  
pp. 60-76
Author(s):  
G. P. Guens ◽  
V. D. Sanikovich ◽  
V. A. Mileyko ◽  
A. A. Lebedeva
Keyword(s):  
Genetic Disorders ◽  
Antiangiogenic Therapy ◽  
Molecular Genetic ◽  
Gene Mutations ◽  
Clinical Results ◽  
Genetic Changes ◽  
Viral Therapy ◽  
The Central Nervous System ◽  
New Treatment ◽  
Methods Of Treatment

Glioblastoma multiforme is the most common and malignant primary tumor of the central nervous system. Despite the existing modern complex therapy and advances in the study of molecular genetic changes in this tumor, the prognosis for patients with glioblastoma is one of the most unfavorable in oncology. This overview reviews existing therapeutic agents and clinical studies of potential drugs for the treatment of patients with glioblastoma multiforme.Next-generation sequencing has become firmly established in the clinical practice of oncologists and allows detecting gene mutations in tumor cells, some of which can serve as targets for therapy. Glioblastoma is characterized by a large number of potentially targeted molecular genetic disorders. As in the case of other solid tumors, targeted and immunotherapy for glioblastomas is being actively studied, including the combination of drugs with physical methods of exposure. To date, new treatment methods of glioblastoma, including antiangiogenic therapy, immunotherapy, oncolytic viral therapy and gene therapy still have uncertain or very modest clinical results. There are many reasons for the lack of progress in the treatment of glioblastoma – from the banal inability of most molecules to overcome the blood-brain barrier to the wide genetic heterogeneity of these tumors. The most promising direction of studies is immunotherapy. But at this stage, we cannot say that there is an effective monotherapy for glioblastoma. The combination treatment with radiation therapy and chemotherapy increases the mutational load, the expression of stress and other factors, therefore, the researchers pin great hopes on the combined methods of treatment.

Prospects in treatment of multiple sclerosis: near future

2020 ◽  
Vol 28 (3) ◽  
pp. 377-390
Author(s):  
Gennadii E. Sheiko ◽  
Anna N. Belova ◽  
Maksim N. Kudykin
Keyword(s):  
Multiple Sclerosis ◽  
Modern Science ◽  
Therapeutic Approaches ◽  
New Methods ◽  
New Therapeutic Approaches ◽  
The Central Nervous System ◽  
Unclear Etiology ◽  
Near Future ◽  
The Given ◽  
Methods Of Treatment

Multiple sclerosis (MS) is a widespread dysimmune-neurodegenerative disease of the central nervous system of unclear etiology. Despite significant achievements in the therapy of MS, the level of progressing disability and early mortality remains alarmingly high. The main aim of the given review is to give a detailed description of new promising medical drugs for treatment of MS. In the article the data of preclinical and clinical trials are given, presumptive mechanisms of the medical drugs under development are described. Development of new therapeutic approaches in treatment of MS is of great interest in modern science. The given review highlights new methods of treatment that are now undergoing clinical trialы and will probably come to the clinical practice in the near future.

Sign in / Sign up

Export Citation Format

Share Document